

# Artificial pancreas device system

Clinical Policy ID: CCP.1205

Recent review date: 2/2024

Next review date: 6/2025

Policy contains: Continuous glucose monitoring; continuous subcutaneous insulin infusion; nocturnal hypoglycemia; Type 1 diabetes.

*First Choice Next has developed clinical policies to assist with making coverage determinations. First Choice Next's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered by First Choice Next when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. First Choice Next's clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. First Choice Next's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, First Choice Next will update its clinical policies as necessary. First Choice Next's clinical policies are not guarantees of payment.*

## Coverage policy

The artificial pancreas device system is clinically proven and, therefore, may be medically necessary in carefully selected members with Type 1 diabetes mellitus when used in accordance with U.S. Food and Drug Administration (2013, 2016a, 2016b) requirements and all of the following criteria are met (American Diabetes Association, 2022; Handelsman, 2015):

- Member requires continuous subcutaneous insulin infusion (insulin pump therapy) and continuous monitoring and trending of their interstitial glucose levels.
- Member has used insulin pump therapy for more than six months.
- Member is at risk of hypoglycemia (e.g., at least two documented events of nocturnal hypoglycemia or hypoglycemia unawareness in a two-week period).
- Member is motivated and knowledgeable in diabetes self-care, including insulin adjustment.
- One of the following U.S. Food and Drug Administration-approved devices is available in states where the device is on the fee schedule:
- MiniMed® 530G with Enlite® Sensor (Medtronic Inc., Northridge, California) for members ages 16 years and older.
- MiniMed® 630G Insulin Pump System with SmartGuard™ technology (Medtronic Inc., Northridge, California) for members ages 16 years and older.
- MiniMed® 670G System with SmartGuard® Hybrid Closed Loop technology (Medtronic Inc., Northridge, California) for members ages 14 years and older.

## Limitations

All other uses of an artificial pancreas device system are not medically necessary.

An artificial pancreas device system not U.S. Food and Drug Administration-approved for commercial use is not medically necessary.

The Medtronic MiniMed 670G System is not medically necessary for members under the age of seven years or who require less than a total daily insulin dose of eight units per day because the device requires a minimum of eight units per day to operate safely (U.S. Food and Drug Administration, 2016b).

An artificial pancreas device system is not medically necessary for members with any of the following criteria, including, but not limited to (American Diabetes Association, 2022; Handelsman, 2015; U.S. Food and Drug Administration, 2013, 2016a, 2016b):

- Unwilling or unable to perform a minimum of four blood glucose tests per day.
- Unwilling or unable to maintain contact with their health care professional.
- Pregnancy.
- Vision or hearing does not allow recognition of pump signals and alarms.
- Receiving dialysis.
- In the previous six months, documentation of one or more of the following:
  - Experienced more than one episode of severe hypoglycemia, defined as a hypoglycemic event requiring assistance of another person to actively administer carbohydrates or glucagon, or to take other corrective actions.
  - Hospitalization or a hospital emergency room visit for uncontrolled diabetes.
  - Diabetic ketoacidosis.

## Alternative covered services

- Multiple daily injections of insulin.
- Non-disposable external continuous infusion insulin pumps.
- Real-time continuous glucose monitoring.
- Blood glucose self-monitoring (finger stick).

## **Background**

Intensive insulin therapy is an aggressive treatment approach for persons with diabetes who require close monitoring of blood glucose levels and frequent doses of insulin. Innovations in insulin delivery and glucose monitoring are designed to improve glycemic control and quality of life while limiting adverse effects, such as hypoglycemia and weight gain (Seaquist, 2013). These advances include continuous subcutaneous insulin infusion, real-time continuous glucose monitoring and sensor-augmented pumps, which combine real-time continuous glucose monitoring with continuous subcutaneous insulin infusion. Intensive insulin therapy consists of continuous subcutaneous insulin infusion using rapid-acting insulin or multiple daily injections (at least three) along with glucose monitoring. Audible and/or vibratory alarms may be helpful in avoiding severe hypoglycemic events, particularly at night.

Despite these developments, a substantial proportion of individuals with insulin-dependent diabetes cannot achieve adequate glycemic control. Nocturnal hypoglycemia, in particular, may impact one's sense of well-being on the following day because of its impact on sleep quantity and quality (Seaquist, 2013).

An artificial pancreas device system combines a continuous glucose monitoring system, an insulin pump, and a control algorithm to closely mimic the glucose-regulating function of a healthy pancreas. The ideal system would

monitor glucose levels in the body and automatically adjust the delivery of insulin to reduce hyperglycemia and minimize hypoglycemia with little or no input from the patient. The U.S. Food and Drug Administration (2018) classifies artificial pancreas device systems as follows:

- The threshold suspend system, also called the low glucose suspend system (product code OZO), reduces the severity of or reverses hypoglycemia by temporarily suspending insulin delivery when the glucose level falls or approaches a low glucose threshold. This system serves as a potential backup when a patient is unable to respond to a hypoglycemic event. Approved devices are the MiniMed 530G and the MiniMed 630G systems (U.S. Food and Drug Administration, 2013, 2016a).
- Insulin-only system (product code OZP) achieves a target glucose level by automatically increasing or decreasing the amount of insulin infused based on specified thresholds of measured glucose levels. The only U.S. Food and Drug Administration-approved system is the MiniMed® 670G Hybrid Closed Loop system (U.S. Food and Drug Administration, 2016b).
- Bi-hormonal control system (product code OZQ) achieves a target glucose level by using two algorithms to instruct an infusion pump to deliver insulin to lower glucose levels and another (e.g., glucagon) to increase blood glucose levels. The bi-hormonal system mimics the glucose-regulating function of a healthy pancreas more closely than an insulin-only system. As of this writing, no products have been approved for commercial use.

The U.S. Food and Drug Administration issued premarket approvals for the MiniMed 530G (P120010) and the MiniMed 630G (P150001) for individuals ages 16 years and older who require insulin as well as continuous monitoring and trending of their interstitial glucose levels. It is intended for continuous delivery of basal insulin (at user-selectable rates) and administration of insulin boluses (in user-selectable amounts). Neither system is intended to be used directly for preventing or treating hypoglycemia; they are intended to suspend insulin delivery when the user is unable to respond to the threshold suspend alarm and indicate when a finger stick may be required.

The U.S. Food and Drug Administration (2016b) approved the MiniMed 670G (P160017) for continuous delivery of basal insulin (at user-selectable rates) and administration of insulin boluses (in user-selectable amounts) for the management of Type 1 diabetes mellitus in persons ages 14 years and older requiring intensive insulin therapy and continuous monitoring and trending of glucose levels in subcutaneous fluid. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by these devices.

## Findings

We identified one systematic review, one additional comparative study, two evidence-based guidelines, and no economic analyses for this policy. The evidence is limited to two studies reporting results from the Automation to Simulate Pancreatic Insulin Response (ASPIRE) trial (Bergenstal, 2013; ClinicalTrials.gov identifier NCT01497938; Weiss, 2015). ASPIRE is a multicenter, in-home, randomized study comparing the effect of the Paradigm Veo® pump (marketed in the United States as the MiniMed 530G) with a threshold suspend feature and continuous glucose monitoring to the Paradigm® Revel™ 2.0 pump (Medtronic Inc., Northridge, California) with a continuous glucose monitoring device in persons with Type 1 diabetes. The primary safety outcome was change in glycated hemoglobin levels from the beginning to the end of the trial. The primary outcome measure was the area under the sensor glucose concentration time curve for nocturnal hypoglycemic events.

Compared with a sensor-augmented pump only, preliminary results suggest the threshold suspend feature reduces both the frequency and overall burden of hypoglycemia without raising glycated hemoglobin and nocturnal hypoglycemia when patients fail to respond (Bergenstal, 2013; Weiss, 2015). However, a critical

appraisal of the studies found several limitations (Blue Cross Blue Shield Association Technology Evaluation Center, 2014):

- The studies included only patients with Type 1 diabetes who were hypoglycemia-prone with two hypoglycemic episodes in the two-week run-in phase but not too ill (i.e., not recently hospitalized or treated in emergency department), thus limiting the generalizability of the results.
- The study had a short follow-up and was underpowered to detect differences in clinical hypoglycemic events, such as severe hypoglycemia.
- Although the threshold suspend was initially set at 70 mg/dL, it could have been changed subsequently to be set between 70 mg/dL and 90 mg/dL. The investigators did not mention whether such differences in thresholds were taken into account in the analyses. The impact of the artificial pancreas with threshold suspend feature would also vary with the percentage of time it is worn.
- There was only a 5 mg/dL difference between initiation of the threshold suspend and reaching a hypoglycemic level (70 mg/dL versus 65 mg/dL). It is unclear how the threshold suspend feature would reduce hypoglycemic episodes.
- It is unclear whether subjects consumed food or glucose during the four hours after suspending insulin delivery.
- The area under the sensor glucose concentration time curve used to measure nocturnal hypoglycemia events combines the duration of hypoglycemia and its severity. This measure is not an indicator used in clinical practice, and it may magnify the effect of an individual dimension used in its calculation (e.g., duration and glucose levels). This study reported differences between study arms in glucose levels below 70 mg/dL, but it did not directly compare the time in hypoglycemia between the two groups.

A search of the U.S. Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database (2023) retrieved more than 500 adverse events associated with the MiniMed 530G system and 46 adverse events associated with the MiniMed 530G with the Enlite Sensor. In its approval of the MiniMed 530G system, the U.S. Food and Drug Administration (2013) listed several contraindications to use:

- Persons unwilling or unable to perform a minimum of four blood glucose tests per day.
- Persons unwilling or unable to maintain contact with their health care professional.
- Persons whose vision or hearing does not allow recognition of pump signals and alarms.
- The Enlite Serter should not be used on products other than the Enlite Sensor. Medtronic cannot guarantee this product's safety or efficacy if used on other products.

The American Association of Clinical Endocrinologists/American College of Endocrinology recommends sensor-augmented continuous subcutaneous insulin infusion, including those with a threshold suspend function, for patients with Type 1 diabetes and patients with Type 2 diabetes who are insulin dependent and at risk of hypoglycemia (Handelsman, 2015). The American Diabetes Association (2022) recommends a sensor-augmented, low glucose threshold suspend pump for patients with frequent nocturnal hypoglycemia and/or hypoglycemia unawareness. Both organizations base their recommendations on the results of the ASPIRE trial and recognize that the threshold suspend feature is an important advancement toward an automatic or semiautomatic closed-loop insulin delivery device.

Adding the threshold suspend feature is a small but important incremental step toward developing a full artificial pancreas device system. Although the results of this single trial are generally favorable, the study has limitations. Medtronic Inc. is conducting a post-approval trial (ClinicalTrials.gov identifier NCT02003898) and a trial of the MiniMed 530G in pediatric populations ages 7 to 15 years (ClinicalTrials.gov identifier NCT02120794). While the results of these studies are needed to confirm the device's safety and efficacy before widespread clinical use, it may benefit some persons who are insulin dependent with frequent nocturnal hypoglycemia and/or hypoglycemia unawareness.

In 2017, the U.S. Food and Drug Administration issued premarket approval to two Medtronic devices: the Medtronic MiniMed 670G System and the MiniMed 630G System. As with the MiniMed 530G, the continuous glucose monitoring component is intended to indicate when a finger stick measurement should be taken, and is not the basis of manual insulin therapy adjustments. Both systems require a prescription (U.S. Food and Drug Administration, 2016a, 2016b).

Greater reliance on automation of blood glucose measurement and insulin delivery, particularly in pediatric populations, requires clearly established safety and efficacy data before incorporating this device into advanced diabetes care. Studies of the MiniMed 670G in children ages 7 to 15 years (ClinicalTrials.gov identifier: NCT02660827) and in persons ages 7 to 75 years (ClinicalTrials.gov identifier: NCT02748018) are ongoing. Therefore, no policy changes are warranted at this time.

In 2018, we identified one new systematic review (Weisman, 2017), one guideline update (from the American Diabetes Association), one small study of the MiniMed 670G in pregnant women (Stewart, 2016), and three trial publications of the MiniMed 670G from the same investigator group (Bergenstal, 2016; Cordero, 2017; Garg, 2017) for this policy. The MiniMed 670G is a safe alternative to conventional pump therapy, improves time in target glycemic range, and reduces glycated hemoglobin, hyperglycemia, and hypoglycemia in adolescent and adult populations with Type 1 diabetes.

Individuals with and without continuous glucose monitoring experience can benefit from this device. Closed-loop systems may have advantages over sensor-augmented pump therapy in specific populations, such as pregnant women with Type 1 diabetes and those with a history of nocturnal hypoglycemia (American Diabetes Association, 2022; Stewart, 2016). However, the U.S. Food and Drug Administration has not approved any of these devices for use in pregnant women. Consequently, the policy is revised to include the MiniMed 630G and 670G as medically necessary in carefully selected non-pregnant patients with Type 1 diabetes.

In 2019, we updated the latest guideline from the American Diabetes Association and added a systematic review and meta-analysis (Bekiari, 2018), with no changes to the policy. The policy ID was changed from CP# 08.02.07 to CCP.1205.

In 2020, we updated the latest guideline from the American Diabetes Association. We also added two studies of the Medtronic MiniMed 670G in participants with Type 1 diabetes that demonstrated the feasibility and safety of a new algorithmic enhancement (de Bock, 2018) and cost effectiveness (Jendle, 2019) compared to continuous subcutaneous insulin infusion from the Swedish perspective at a willingness-to-pay threshold of SEK 300,000 per quality-adjusted life year gained. We added one systematic review (Munoz-Velandia, 2019) of eight quantitative and 11 qualitative studies of patient values and preferences of continuous subcutaneous insulin infusion or artificial pancreas treatment that may inform choice of delivery system in adults with Type 1 diabetes. The key driver of patients' preferences was glycemic control, followed by reductions in glycemic variability, hypoglycemic episodes, and chronic complications, and components of treatment burden (e.g., device size, appearance, and cost, ease of use, and the embarrassment of public use). The new findings warrant no changes to the policy.

In 2021, we updated the American Diabetes Association's latest guideline and added one systematic review (Asarani, 2021) to the policy. Both references address the increasing use of "do-it-yourself" artificial pancreas systems among individuals with Type 1 diabetes. These systems automate insulin delivery with existing, commercially-available pumps and real-time continuous glucose monitoring combined with open-source algorithms. The results of a systematic review (Asarani, 2021) of 10 low-quality studies (n = 730 participants) suggest improvements in time in range, HbA1c, hypoglycemia, and quality of life with the use of do-it-yourself systems, but the results need to be confirmed in well-designed randomized trials. The U.S. Food and Drug Administration has not yet approved these systems. No policy changes are warranted.

In 2022, we updated the American Diabetes Association's latest guideline (2021). We also added a systematic review/meta-analysis of six randomized controlled trials that compared time in range between fully closed-loop systems and standard of care during physical exercise in 266 people with type 1 diabetes. Time in range was higher in favor of closed-loop systems, especially among children and adolescents (Eckstein, 2021). We also included a randomized trial ( $n = 36$ ) that found closed-loop automated insulin delivery (artificial pancreas) improves glucose control compared with sensor-augmented pump therapy, confirming the conclusions of eight other trials since 2015 (Haidar, 2021).

In 2023, we updated the American Diabetes Association's latest guideline (2022). We also added

- A systematic review/meta-analysis of 12 randomized trials found closed-loop insulin delivery was superior in blood glucose control than insulin sensor-augmented pump delivery. Metrics included average blood glucose value ( $P = .003$ ); time in range ( $P < .00001$ ); low blood glucose index ( $P < .00001$ ), high blood glucose index ( $P < .00001$ ), and adverse effects ( $P = .001$ ) (Fang, 2022).
- A systematic review/meta-analysis of 25 studies ( $n = 504$ ), compared closed-loop artificial pancreas systems with continuous subcutaneous insulin infusion in persons with diabetes  $<18$  years of age. Results in the closed loop group were superior (higher percent of time spent in the target glycemic range, lower percent of time in hyperglycemia/hypoglycemia, and lower mean glucose (Karageorgiou, 2019).
- A review of 123,355 users of the MInimed 670G system in 2017-2020,  $> 7$  years, with  $>10$  days of treatment, found significant improvements (versus pre-auto mode initiation), including a decrease in mean glucose management indicator ( $P < .001$ ), an increase in time spent in target range ( $P < .001$ ), and decreases in time spent above or below target range ( $P < .001$ ,  $P = .002$ ) (Arunachalum, 2023).

In 2024, we added a guideline that supported use of closed-loop systems for persons with type 1 diabetes (National Institute for Health and Care Excellence, 2023). We also added large reviews of persons with type 1 diabetes, including:

- A systematic review/meta-analysis of 41 studies of outpatients documented superior outcomes after treatment with artificial pancreas versus conventional insulin therapy, for higher time in the target range in overnight use and lower time in the hypoglycemic range ( $P < .00001$ ) (Kang, 2022).
- A meta-analysis of 11 studies ( $n = 570$ ) of adolescents showed superior control of blood glucose for closed-loop systems, compared to sensor-augmented pumps (Jabari, 2023).
- A systematic review of 30 papers on children, adolescents, and young adults concluded the MiniMed 670G system improved metrics up to one year after treatment, but improvements are not as great as in advanced hybrid closed loop systems (Mameli, 2023).
- A systematic review/meta-analysis of 26 randomized trials of children and adolescents ( $n = 915$ ) found automated insulin delivery systems were superior to controls (insulin pump therapy, sensor-augmented pumps, and multiple daily injections) in proportion of time in the target glucose range ( $P < .00001$ ), hypoglycemia ( $P = .003$ ), and mean proportion of HbA1C ( $P = .0007$ ) (Michou, 2023).

## References

On November 3, 2023, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were “pancreas, artificial” (MeSH), “Islets of Langerhans Transplantation” (MeSH), and the free-text terms “bionic pancreas” and “artificial pancreas. We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.



American Diabetes Association Professional Practice Committee: Draznin B, Aroda VR, Bakris G, et al. *Diabetes Care*. 2022;45(Suppl 1):S97-S112. Doi: 10.2337/dc22-S007. [https://diabetesjournals.org/care/issue/45/Supplement\\_1](https://diabetesjournals.org/care/issue/45/Supplement_1).

Arunachalum S, Velado K, Vigersky RA, Cordero TL. Glycemic outcomes during real-world hybrid closed-loop system use by individuals with type 1 diabetes in the United States. *J Diabetes Sci Technol*. . Doi: 10.1177/19322968221088608.2023;17(4):951-958.

Asarani NAM, Reynolds AN, Elbalshy M, et al. Efficacy, safety, and user experience of DIY or open-source artificial pancreas systems: A systematic review. *Acta Diabetol*. 2021;58(5):539-547. Doi: 10.1007/s00592-020-01623-4.

Bekiari E, Kitsios K, Thabit H, et al. Artificial pancreas treatment for outpatients with Type 1 diabetes: Systematic review and meta-analysis. *BMJ*. 2018;361:k1310. Doi: 10.1136/bmj.k1310.

Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with Type 1 diabetes. *JAMA*. 2016;316(13):1407-1408. Doi: 10.1001/jama.2016.11708.

Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. *N Engl J Med*. 2013;369(3):224-232. Doi: 10.1056/NEJMoa1303576.

Blue Cross Blue Shield Association, Kaiser Permanente. *Artificial pancreas device systems*. Tech Eval Cent Assess Program Eval Summ. 2014;28(14):1-4. <https://pubmed.ncbi.nlm.nih.gov/24933743/>.

Cordero TL, Garg SK, Brazg R. The effect of prior continuous glucose monitoring use on glycemic outcomes in the pivotal trial of the MiniMed – 67G hybrid closed-loop system. *Diabetes Technol Ther*. 2017;19(12):749-752. Doi: 10.1089/dia.2017.0208.

de Bock M, Dart J, Hancock M, et al. Performance of Medtronic hybrid closed-loop iterations: Results from a randomized trial in adolescents with Type 1 diabetes. *Diabetes Technol Ther*. 2018;20(10):693-697. Doi: 10.1089/dia.2018.0161.

Eckstein ML, Weilguni B, Tauschmann M, et al. Time in range for closed-loop systems versus standard of care during physical exercise in people with type 1 diabetes: A systematic review and meta-analysis. *J Clin Med*. 2021;10(11):2445. Doi: 10.3390/jcm10112445.

Fang Z, Liu M, Tao J, Li C, Zou F, Zhang W. Efficacy and safety of closed-loop insulin delivery versus sensor-augmented pump in the treatment of adults with type 1 diabetes: A systematic review and meta-analysis of randomized-controlled trials. *J Endocrinol Invest*. 2022;45(3):471-481. Doi: 10.1007/s40618-021-01674-6.

Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with Type 1 diabetes. *Diabetes Technol Ther*. 2017;19(3):155-163. Doi: 10.1089/dia.2016.0421.

Haidar A, Legault L, Raffray M, et al. Comparison between closed-loop insulin delivery system (the artificial pancreas) and sensor-augmented pump therapy: A randomized-controlled crossover trial. *Diabetes Technol Ther.* 2021;23(3):168-174. Doi: 10.1089/dia.2020.0365.

Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology — clinical practice guidelines for developing a diabetes mellitus comprehensive care plan — 2015. *Endocr Pract.* 2015;21 Suppl 1:1-87. Doi: 10.4158/EP15672.GL.

Jabari M. Efficacy and safety of closed-loop control system for type one diabetes in adolescents a meta-analysis. *Sci Rep.* 2023;13(1):13165. Doi: 10.1038/s41598-023-40423-y.

Jendle J, Pohlmann J, de Portu S, Smith-Palmer J, Roze S. Cost-effectiveness analysis of the Minimed 670g hybrid closed-loop system versus continuous subcutaneous insulin infusion for treatment of Type 1 diabetes. *Expert Rev Med Devices.* 2019;21(3):110-118. Doi: 10.1089/dia.2018.0328.

Kang SL, Hwang YN, Kwon JY, Kim SM. Effectiveness and safety of a model predictive control (MPC) algorithm for an artificial pancreas system in outpatients with type 1 diabetes (T1D): Systematic review and meta-analysis. *Diabetol Metab Syndr.* 2022;14(1):187. Doi: 10.1186/s13098-022-00962-2.

Karageorgiou V, Papaioannou TG, Bellos I, et al. Effectiveness of artificial pancreas in the non-adult population: A systematic review and network meta-analysis. *Metabolism.* 2019;90:20-30. Doi: 10.1016/j.metabol.2018.10.002.

Mameli C, Smylie GM, Galati A, et al. Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: A systematic review. *Eur J Pediatr.* 2023;182(5):1949-1963. Doi: 10.1007/s00431-023-04833-4.

Michou P, Gkiourtzis N, Christoforidis A, Kotanidou EP, Galli-Tsinopoulou A. The efficacy of automated insulin delivery systems in children and adolescents with type 1 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. *Diabetes Res Clin Pract.* 2023;199:110678. Doi: 10.1016/j.diabres.2023.110678.

Munoz-Velandia O, Guyatt G, Devji T, et al. Patient values and preferences regarding continuous subcutaneous insulin infusion and artificial pancreas in adults with Type 1 diabetes: A systematic review of quantitative and qualitative data. *Diabetes Technol Ther.* 2019;21(4):183-200. Doi: 10.1089/dia.2018.0346.

National Institute for Health and Care Excellence. Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. Technology appraisal guidance TA943. <https://www.nice.org.uk/guidance/ta943>. Published December 19, 2023.

Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. *Diabetes Care.* 2013;36(5):1384-1395. Doi: 10.2337/dc12-2480.

Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-loop insulin delivery during pregnancy in women with Type 1 diabetes. *N Engl J Med.* 2016;375(7):644-654. Doi: 10.1056/NEJMoa1602494.



U.S. Food and Drug Administration. MAUDE - Manufacturer and User Facility Device Experience using search terms “Minimed 530G” and selecting “All years.” Page last updated September 30, 2023.

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/TextSearch.cfm>.

U.S. Food and Drug Administration. Premarket approval letter (P120010). MiniMed 530G System.

[http://www.accessdata.fda.gov/cdrh\\_docs/pdf12/P120010A.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf12/P120010A.pdf). Published September 26, 2013.

U.S. Food and Drug Administration. Premarket approval letter (P150001). MiniMed 630G System with

SmartGuard™. [https://www.accessdata.fda.gov/cdrh\\_docs/pdf15/P150001A.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150001A.pdf). Published August 10, 2016.

(a)

U.S. Food and Drug Administration. Premarket Approval Letter (P160017). MiniMed 670G System.

[http://www.accessdata.fda.gov/cdrh\\_docs/pdf16/P160017a.pdf](http://www.accessdata.fda.gov/cdrh_docs/pdf16/P160017a.pdf). Published September 28, 2016. (b)

U.S. Food and Drug Administration. The artificial pancreas device system.

<http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/HomeHealthandConsumer/ConsumerProducts/ArtificialPancreas/default.htm>. Last updated August 30, 2018.

Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with Type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. *Lancet Diabetes Endocrinol*. 2017;5(7):501-512. Doi: 10.1016/s2213-8587(17)30167-5.

Weiss R, Garg SK, Bode BW, et al. Hypoglycemia reduction and changes in hemoglobin A1c in the ASPIRE In-Home Study. *Diabetes Technol Ther*. 2015;17(8):542-547. Doi: 10.1089/dia.2014.0306.

## Policy updates

11/2015: initial review date and clinical policy effective date: 4/2016

2/2017: Policy references updated.

2/2018: Policy references updated. Policy coverage modified.

2/2019: Policy references updated. Policy ID changed.

2/2020: Policy references updated.

2/2021: Policy references updated.

2/2022: Policy references updated.

2/2023: Policy references updated.

2/2024: Policy references updated.